We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Denise Roland
AstraZeneca PLC (AZN.LN) swung to a net profit in the second quarter, thanks to lower spending on research and marketing, proceeds from several licensing deals, and a favorable year-earlier comparison, though revenue fell as sales of new drugs struggled to offset the decline of the company's old best-sellers.
Cambridge, England-based AstraZeneca posted net profit of $477 million, compared with a $3 million net loss a year earlier, when the company took a restructuring charge related to job cuts. Revenue dropped 10% to $5.05 billion. Analysts had expected net profit of $450 million on revenue of $5.05 billion.
AstraZeneca's top line has been shrinking for several years as its historic best-sellers such as cholesterol-lowering pill Crestor lose patent protection, allowing cheap copycats to enter the market. Chief Executive Pascal Soriot has promised investors that 2017 will be the year when sales bottom out.
Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
July 27, 2017 02:38 ET (06:38 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
